Stock Financial Ratios

JUNO / Juno Therapeutics, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)5,148.10
Enterprise Value ($M)4,333.52
Book Value ($M)1,077.70
Book Value / Share10.62
Price / Book4.49
NCAV ($M)1,234.57
NCAV / Share12.17
Price / NCAV4.17
Income Statement (mra) ($M)
Net Income-245.58
Balance Sheet (mrq) ($M)
Cash & Equivalents449.84
Cash / Share4.43
Quick Ratio6.72
Current Ratio6.72
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.23
Return on Assets (ROA)-0.18
Return on Equity (ROE)-0.23
Identifiers and Descriptors
Central Index Key (CIK)1594864
Industry Groups
SIC 2836 - Biological Products, Except Diagnostic Substances (Biotech)
Other Related CUSIPS
Share Statistics
Common Shares Outstanding (M)114.17
Scoring Models
Piotroski F Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Assets Per Share15.12
Accounts Receivable Per Share0.34
Inventory Raw Materials Per Share0.00
Assets Current Per Share9.58
Treasury Stock Per Share0.00
Cash Per Share4.43
Accounts Payable Per Share0.00
Long Term Debt Per Share0.10
Liabilities Current Per Share2.01
Property Plant And Equipment Per Share1.30
Inventory Per Share0.00
Debt Per Share0.11
Deferred Income Tax Liabilities Per Share0.02
Inventory Work In Progress Per Share0.00
Liabilities And Stock Equity Per Share15.12
Intangibles Per Share0.76
Current Portion Of Long Term Debt Per Share0.00
Property Plant And Equipment Net Per Share1.30
Equity Per Share11.31
Cash And Equivalents Per Share4.43
Assets Other Current Per Share0.00
Inventory Finished Goods Per Share0.00
Liabilities Other Non Current Per Share0.00
Retained Earnings Per Share-11.16
Preferred Stock Value Outstanding Per Share0.00
Assets Non Current Per Share0.00
Goodwill Per Share2.18
Accumulated Depreciation And Depletion Per Share0.00
Assets Other Non Current Per Share0.04
Minority Interest Per Share0.00
Additional Paid In Capital Per Share22.44
Liabilities Per Share3.81
Property Plant And Equipment Gross Per Share0.00

Related News Stories

3 Stocks to Watch on Wednesday: Adient PLC (ADNT), Interactive Brokers Group, Inc. (IBKR) and Juno Therapeutics Inc (JUNO)

34m investorplace
The day started off well as the Dow Jones Industrial Average surged above 26,000 before coming back down to Earth, while mining stocks fell 1.4%. At the end of Tuesday, the Dow Jones was down a fraction, while the S&P 500 Index lost 0.4% and the Nasdaq Composite slipped 0.5%. (39-0)

Deals of the day-Mergers and acquisitions

2h reuters
Jan 17 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1100 GMT on Wednesday: (63-0)

U.S. Biotech/Pharma Sector Daily Observations Letter: January 16, 2018

4h seekingalpha
There was a sharp pullback in the U.S. market indexes due to fear of government shutdown. (173-0)

Biotech Analysis Central Pharma News: Merck's Keytruda Rises, Celgene's Possible Next Move, Eiger's Phase 2 Dip

5h seekingalpha
Merck gains an edge over Bristol-Myers and Roche after positive phase 3 data in first-line non-small cell lung cancer. (81-0)

PRESS DIGEST- Wall Street Journal - Jan 17

7h reuters
Jan 17 (Reuters) - The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy. (75-0)

CUSIP: 48205A109